CBS 2019
CBSMD教育中心
中 文

Other Relevant Articles

Abstract

Recommended Article

Microthrombi As A Major Cause of Cardiac Injury in COVID-19: A Pathologic Study Defining Staged Procedures for Percutaneous Coronary Intervention Trials A Guidance Document Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial Randomized Comparison of Ridaforolimus-Eluting and Zotarolimus-Eluting Coronary Stents 2-Year Clinical Outcomes: From the BIONICS and NIREUS Trials Major infections after bypass surgery and stenting: an overlooked but fatal complication Safety and feasibility of robotic percutaneous coronary intervention: PRECISE (Percutaneous Robotically-Enhanced Coronary Intervention) Study How Low to Go With Glucose, Cholesterol, and Blood Pressure in Primary Prevention of CVD Sudden Cardiac Arrest Survivorship: A Scientific Statement From the American Heart Association

ConsensusNovember 2018

JOURNAL:J Am Coll Cardiol. Article Link

2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways

Writing Committee, Sandeep RD, Brendan M et al. Keywords: ASCVD; cardiovascular risk reduction; diabetes; Expert Consensus; Decision Pathway; GLP-1RA; SGLT2 inhibitor; T2D

FULL TEXT PDF